Concurrently, the LAG-3/PD-1 dual-antibody EMB-02 treatment plan for melanoma has been approved [34], suggesting that the treatment of TNBC through dual-antibody combined chemotherapy warrants further investigation. The gene discussed is LAG3; the disease is melanoma.